(Reuters) - As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc, could charge up to $10,000 for the treatment.
The article Big Pharma wages stealth war on drug price watchdog appeared first on Stabroek News.
